Tvardi Therapeutics, Inc.
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $7.1M
- Net income
- -$18.2M
- Total assets
- $32.1M
- Market cap
- $27.1M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $26.7M
- Operating income
- -$26.7M
- Income tax
- $0
- Net income
- -$18.2M
- EPS (basic)
- $-2.46
- EPS (diluted)
- $-3.26
Balance sheet
- Total assets
- $32.1M
- Current assets
- $31.5M
- Total liabilities
- $11.1M
- Current liabilities
- $11.0M
- Shareholders’ equity
- $20.9M
Cash flow
- Operating cash flow
- -$23.5M
- Investing cash flow
- -$10.1M
- Financing cash flow
- $22.7M
- Net cash flow
- -$10.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $27.1M
- EPS (diluted)
- $-3.26
- Shares outstanding
- 9.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 16, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $18.2M in FY2024.
- Trading 93% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tvardi Therapeutics, Inc..
Write a review
News about Tvardi Therapeutics, Inc.
News & sentiment via Polygon.io
